Progenics: Corporate Presentation (Progenics) - Oct 2, 2015 - "PSMA ADC: Phase 2 Results"; "Strong anti-tumor activity: Complete and partial radiologic responses and stable disease seen in 93% of chemo-naïve and 86% of all patients, CTC declines of ≥50% in 89% of chemo-naïve and 78% of all patients, Conversion from unfavorable to favorable CTC status in 53% of chemo-naïve and 47% of all patients, PSA declines of ≥30% seen in 32% of chemo--naïve and 30% of all patients, Responses continue to be more prominent in patients with high PSMA expression and low neuroendocrine biomarkers,"; "Responses comparable to those seen for approved therapies" P2 data • Oncology
|